Uveitis: Opportunity Assessment and Forecast - Update
Summary
This report covers the 7MM (US, 5EU, Japan) and provides an Excel-based forecast model for the uveitis market through 2033.
There will be an overall increase in the diagnosed prevalent cases of uveitis in the 7MM across the forecast period.
Across the 7MM, the mainstay treatment for uveitis involves the use of anti-inflammatory therapies.
Significant clinical unmet needs remain in the uveitis market.
The late-stage uveitis pipeline consists of six agents.
The uveitis market in the 7MM was valued at $522.5 million in 2023. The market is projected to grow at a CAGR of 10.9%, reaching $1.5 billion by 2033.
Scope
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook